Transce3nd’s AstraZeneca AZN Stock Holding History

Transce3nd’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13	Closed	-$1.75K	–	230
2025 Q2	$1.75K	Hold	13	–	–	﹤0.01%	906
2025 Q1	$1.84K	Sell	13 -1	-7%	-$145	﹤0.01%	873
2024 Q4	$1.77K	Buy	+14	New	+$1.96K	﹤0.01%	1121

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Transce3nd's AZN Position: Q3 2025 in Review

Transce3nd sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 13 shares — an estimated $1.75K sold.

Transce3nd first reported a position in AZN in Q4 2024 and held it in 3 quarters. The position peaked at $1.84K in Q1 2025. 1,287 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

Transce3nd reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
Transce3nd sold 13 AstraZeneca shares in Q3 2025, an estimated $1.75K.
Transce3nd first reported a position in AstraZeneca in Q4 2024 and held it in 3 quarters.
Transce3nd's AstraZeneca position peaked at $1.84K in Q1 2025.
1,287 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.